

December 4, 2014

ContraFect

MOLECULAR TREATMENTS
FOR INFECTIOUS DISEASE



ContraFect Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference

YONKERS, NY -- (Marketwired) -- 12/04/14 -- [**ContraFect Corporation**](#) (NASDAQ: CFRX) (NASDAQ: CFRXW) (NASDAQ: CFRXZ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that Julia P. Gregory, the Company's chief executive officer, will present a corporate overview at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10, 2014 at 4:30 PM ET. Ms. Gregory will discuss ContraFect's lead programs, CF-301, which provides a novel approach to the treatment of drug-resistant *Staphylococcus aureus* infections and CF-404, a universal treatment for life-threatening influenza infections.

The presentation will be available as a webcast for a limited time. To access via the Company's website, please go to www.contrafect.com. To access the webcast directly, please use the following URL:

<http://www.veracast.com/webcasts/opco/healthcare2014/34115482044.cfm>

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans,"

"potential" or similar references to future periods. Examples of forward-looking statements include statements made regarding ContraFect's therapeutic product candidates. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results or the lack of regulatory approval. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

Barry Kappel, Ph.D., MBA
SVP Business Development
Tel: 914-207-2300
E-Mail: [Email Contact](#)
or visit: www.contrafect.com

Source: ContraFect Corporation